Background: Ibrutinib has revolutionized treatment for several B-cell malignancies. However, a recent clinical trial where ibrutinib was used in front-line setting showed increased mortality during treatment compared to conventional chemotherapy. Cardiovascular toxicities were suspected as the culprit but not directed assessed in the study. Objective: We aimed to identify and characterize cardiovascular adverse drug reactions (CV-ADR) associated with ibrutinib. Methods: We utilized VigiBase (International pharmacovigilance database) and performed a disproportionality analysis using reporting odds-ratios (ROR) and information component (IC) to determine whether CV-ADR and CV-ADR deaths were associated with ibrutinib. IC compares observed and expected values to find associations between drugs and ADR using disproportionate Bayesianreporting; IC025 (lower end of the IC 95% credibility interval)> 0 is significant. Results: We identified 303 ibrutinib-associated cardiovascular deaths. Ibrutinib was associated with